CL2021000347A1 - Polipéptidos de unión a ox40 y sus usos - Google Patents

Polipéptidos de unión a ox40 y sus usos

Info

Publication number
CL2021000347A1
CL2021000347A1 CL2021000347A CL2021000347A CL2021000347A1 CL 2021000347 A1 CL2021000347 A1 CL 2021000347A1 CL 2021000347 A CL2021000347 A CL 2021000347A CL 2021000347 A CL2021000347 A CL 2021000347A CL 2021000347 A1 CL2021000347 A1 CL 2021000347A1
Authority
CL
Chile
Prior art keywords
binding polypeptides
vhh
containing polypeptides
bind
polypeptides
Prior art date
Application number
CL2021000347A
Other languages
English (en)
Inventor
John C Timmer
William Crago
Kyle S Jones
Katelyn M Willis
Florian Sulzmaier
Bryan Becklund
Brendan P Eckelman
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of CL2021000347A1 publication Critical patent/CL2021000347A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en este documento polipéptidos que contienen VHH que se unen a OX40. En algunas formas de realización, se proporcionan polipéptidos que contienen VHH que se unen a OX40 y lo agonizan. Se proporcionan además usos de los polipéptidos que contienen VHH.
CL2021000347A 2018-08-13 2021-02-09 Polipéptidos de unión a ox40 y sus usos CL2021000347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862718106P 2018-08-13 2018-08-13

Publications (1)

Publication Number Publication Date
CL2021000347A1 true CL2021000347A1 (es) 2021-09-03

Family

ID=67841151

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000347A CL2021000347A1 (es) 2018-08-13 2021-02-09 Polipéptidos de unión a ox40 y sus usos

Country Status (16)

Country Link
US (2) US11447556B2 (es)
EP (1) EP3837285A1 (es)
JP (2) JP7462611B2 (es)
KR (1) KR20210044243A (es)
CN (1) CN112601761A (es)
AR (1) AR114552A1 (es)
AU (1) AU2019321490A1 (es)
BR (1) BR112021002164A2 (es)
CA (1) CA3107767A1 (es)
CL (1) CL2021000347A1 (es)
IL (1) IL280808A (es)
MX (1) MX2021001703A (es)
PH (1) PH12021550289A1 (es)
SG (1) SG11202101173TA (es)
TW (1) TW202019968A (es)
WO (1) WO2020036867A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295324A1 (en) * 2020-06-30 2023-09-21 Harbour Biomed (Shanghai) Co., Ltd Ox40-targeted antibody, and preparation method therefor and application thereof
CN117460746A (zh) * 2021-06-17 2024-01-26 和铂医药(上海)有限责任公司 靶向pd1和/或ox40的特异性结合蛋白
EP4448579A1 (en) * 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
WO2023109900A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
GB202210969D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Activation induced marker assay

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN1871359B (zh) 2003-10-22 2010-11-17 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
PT1877090E (pt) 2005-05-06 2014-04-15 Providence Health System Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CN102245640B (zh) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
UY32451A (es) 2009-02-17 2010-09-30 Ucb Pharma Sa Moléculas de anticuerpo con especifidad por el ox40 humano
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
CA2786660A1 (en) * 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AP2014007791A0 (en) 2012-02-27 2014-07-31 Boehringer Ingelheim Int CX3CR1-binding polypeptides
EP2844289B1 (en) 2012-04-30 2019-07-17 MedImmune, LLC Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP2015524821A (ja) 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
AU2014227638A1 (en) 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
DK2976361T3 (en) 2013-03-18 2018-10-01 Biocerox Prod Bv HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20180033588A (ko) * 2015-08-12 2018-04-03 메디뮨 리미티드 Ｇｉｔｒｌ 융합 단백질 및 그의 용도
AU2017207318B2 (en) * 2016-01-11 2023-12-07 Inhibrx Biosciences, Inc. Multivalent and multispecific OX40-binding fusion proteins
CA3047059A1 (en) 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof

Also Published As

Publication number Publication date
US20200055946A1 (en) 2020-02-20
CA3107767A1 (en) 2020-02-20
MX2021001703A (es) 2021-04-19
WO2020036867A1 (en) 2020-02-20
CN112601761A (zh) 2021-04-02
KR20210044243A (ko) 2021-04-22
US20230128188A1 (en) 2023-04-27
PH12021550289A1 (en) 2021-10-25
SG11202101173TA (en) 2021-03-30
AU2019321490A1 (en) 2021-02-18
US12012459B2 (en) 2024-06-18
EP3837285A1 (en) 2021-06-23
JP2024075739A (ja) 2024-06-04
BR112021002164A2 (pt) 2021-08-03
JP2021533761A (ja) 2021-12-09
JP7462611B2 (ja) 2024-04-05
AR114552A1 (es) 2020-09-16
IL280808A (en) 2021-04-29
AU2019321490A8 (en) 2021-03-25
US11447556B2 (en) 2022-09-20
TW202019968A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
CL2021000347A1 (es) Polipéptidos de unión a ox40 y sus usos
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
AR106583A1 (es) Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CL2021001627A1 (es) Molécula bifuncional anti-pd-1/sirpa
CL2019001646A1 (es) Anticuerpos anti-ox40 y sus usos.
ECSP19058592A (es) Polipéptidos de unión al receptor de transferrina diseñados
UY37258A (es) AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
ECSP21026339A (es) Anticuerpos anti–hla–g, composiciones que comprenden anticuerpos anti–hla–g y métodos de uso de anticuerpos anti–hla–g
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
BR112021011124A2 (pt) Anelossomos e métodos de uso
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
CO2023012821A2 (es) Anticuerpos anti-nectina-4 y usos de los mismos
EA202090335A1 (ru) Взаимоусиливающие комбинации гербицидов